Advances in the treatment of precocious puberty

Expert Opinion on Investigational Drugs

Volumn 10, Issue 9, 2001, Pages 1623-1630

  Eugster, E A ^a   Pescovits, O H ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti oestrogens; Aromatase inhibitors; GnRH analogues; Precocious puberty

Indexed keywords

ABARELIX; ANASTROZOLE; ANTIANDROGEN; AROMATASE INHIBITOR; BUSERELIN; CETRORELIX; DESLORELIN; ESTROGEN; FOLLITROPIN; GONADORELIN; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADOTROPIN; GROWTH HORMONE; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTRELIN; KETOCONAZOLE; LETROZOLE; LEUPRORELIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NAFARELIN; SEX HORMONE; SPIRONOLACTONE; TESTOLACTONE; TESTOSTERONE; TEVERELIX; TRIPTORELIN; UNINDEXED DRUG;

ALBRIGHT SYNDROME; BODY COMPOSITION; BODY HEIGHT; BONE DENSITY; BONE MINERAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MALE; OVARIECTOMY; PRECOCIOUS PUBERTY; REPRODUCTION; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; GONADOTROPIN-RELEASING HORMONE; HUMANS; PUBERTY, PRECOCIOUS;

EID: 0034839183     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.9.1623     Document Type: Review

References (59)

1. Precocious puberty
2. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the pediatric research in office settings network
3. Precocious puberty
4. Review of Precocious Puberty Part II: Gonadotropin-Independent Precocious Puberty
5. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: A potential new treatment for idiopathic precocious puberty
6. The NIH experience in precocious puberty: Diagnostic subgroups and the response to short-term LHRH analogue therapy
7. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty
8. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues
9. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function
10. Central precocious puberty in girls: Internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues
11. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone
12. LHRH Analog treatment of central precocious puberty complicating congenital adrenal hyperplasia
13. Combination treatment with growth hormone and gonadotropin-releasing hormone analogs in short normal girls
14. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: Results from a controlled study
15. Gonadotropin-releasing hormone agonists in the treatment of girls with precocious puberty
16. Ovarian stimulation with HMG: Results of a prospective randomized Phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin
17. The use of gonadotropin-releasing hormone antagonists in polycystic ovarian disease
18. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model
19. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverilix in healthy men-a first-dose-in-humans study
20. Familial male precocious puberty
21. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty
22. A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty
23. A missense mutation in the second transmembrane segment of the luteinizing hormone receptor causes familial male-limited precocious puberty
24. A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty
25. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male precocious puberty
26. A limited repertoire of mutations of the luteinizing hormone receptor gene in familial and sporadic patients with male LH-independent precocious puberty
27. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testitoxicosis): Effects of a potent luteinizing hormone-releasing factor agonist and in four cases
28. Ketoconizole in the management of precocious puberty not responsive to LHRH-analogue therapy
29. Hazards of ketoconazole therapy in testitoxicosis
30. Gonadotropin-independent precocious puberty
31. Long-term outcome of male-limited gonadotropin-independent precocious puberty
32. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
33. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
34. Effect of testosterone and estradiol in a man with aromatase deficiency
35. Treatment of familial male precocious puberty with spironolactone, testolactone and deslorelin
36. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset
37. Activating mutations of the stimulatory G protein in the McCune-Albright Syndrome
38. McCune-Albright Syndrome
39. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gs
40. Ovarian function in girls with McCune-Albright syndrome
41. Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome
42. McCune-Albright Syndrome
43. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright Syndrome
44. The therapeutic potential of novel aromatase inhibitors in breast cancer
45. Use of aromatase inhibitors in precocious puberty
46. Estrogen suppression in males: Metabolic effects
47. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: A randomized controlled trial
48. Estrogen: Consequences and implications of human mutations in synthesis and action
49. The aromatase inhibitor fadrozole is not an effective treatment for the precocious puberty in the McCune-Albright syndrome
50. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome
51. Clinical, hormonal and sonographical characteristics of remission during treatment of pseudoprecocious puberty in the McCune-Albright syndrome
52. Safety and efficacy of tamoxifen therapy in a two year old girl with McCune-Albright syndrome
53. Treatment of marked gynecomastia in puberty with tamoxifen
54. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14
55. Tamoxifen in the treatment of breast cancer
56. Breast carcinoma in an 11 year old girl with Albright's syndrome
57. The effects of the estrogen receptor blocker Faslodex (ICI 182,780), on estrogen-Accelerated bone maturation in Mice
58. ICI 182,780 (Faslodex): Development of a novel, 'pure' antiestrogen
59. Androgen receptor antagonists (antiandrogens): Structure-activity relationships